Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells $1,719,590.07 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) insider John Paolini sold 18,413 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $93.39, for a total transaction of $1,719,590.07. Following the completion of the sale, the insider owned 69,922 shares of the company’s stock, valued at $6,530,015.58. This trade represents a 20.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Up 2.7%

Shares of KNSA stock traded up $2.49 during midday trading on Tuesday, reaching $93.29. 1,021,631 shares of the stock were exchanged, compared to its average volume of 705,858. The firm has a market cap of $7.28 billion, a PE ratio of 71.76 and a beta of 0.04. The company’s 50 day moving average is $79.39 and its two-hundred day moving average is $60.29. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. The company had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. As a group, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Wedbush lifted their price target on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Finally, Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $100.57.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Allworth Financial LP grew its holdings in Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after purchasing an additional 134 shares during the period. Arizona State Retirement System lifted its stake in Kiniksa Pharmaceuticals International by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after purchasing an additional 209 shares in the last quarter. GAMMA Investing LLC boosted its stake in Kiniksa Pharmaceuticals International by 21.1% during the third quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock valued at $95,000 after buying an additional 223 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in Kiniksa Pharmaceuticals International by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock worth $811,000 after acquiring an additional 237 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after acquiring an additional 293 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.